Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Patient Monitoring

See what CB Insights has to offer



Total Raised


Date of IPO


Market Cap


About Breathtec Biomedical

BreathTec offers a non-invasive, alternative medical testing solution for various health-related concerns including cancers, liver disease, kidney failure, diabetes, asthma and tuberculosis.

Breathtec Biomedical Headquarter Location

10589 Ladner Trunk Road

Delta, British Columbia, V4G 1K2,



Latest Breathtec Biomedical News

Nash Pharmaceuticals announces positive pre-clinical results from a second study for chronic kidney...

Feb 14, 2019

Source: CBNB 2019/02/14 Source: Company press release, 14 Jan 2019 , 14 Jan 2019 , Website: Nash Pharmaceuticals Inc, a wholly owned subsidiary of Breathtec Biomedical Inc announced that in a new recent in vivo animal study for chronic kidney disease (CKD), the activity of NP-135 was confirmed, and two additional compounds, NP-160 and NP-251 were identified as new lead compounds in a unilateral ureteral obstruction (UUO) mouse model of kidney fibrosis. Data from this study demonstrated that clinically relevant doses resulted in statistically significant improvements in the reduction in fibrosis in the UUO model as measured by Sirius Red staining over untreated controls. Telmisartan (3mg/kg), a positive control, reduced fibrosis by 32.6% (p less than 0.001). Cenicriviroc (40 mg/kg) a CCR2/5 chemokine receptor antagonist with reported anti-fibrotic activity, reduced fibrosis by 31.9% (p=0.00032). NP-135 (200 mg/kg) reduced fibrosis by 52.1% (p less than 0.000001). In addition, the mass of the fibrotic kidney was lower than the negative control (ie closer to normal, p=0.016). NP-160 (40 mg/kg) reduced fibrosis by 57.6% (p less than 0.000001). NP-160 was also previously reported to be anti-fibrotic in a mouse model of non-alcoholic steatohepatitis (NASH). NP-251 (90 mg/kg) reduced fibrosis by 50.6% (p less than 0.000001) with evidence of slight synergy (54.2% reduction in fibrosis, p less than 0.000001) when a low dose (30 mg/kg, 20.8% reduction in fibrosis, p more than 0.05) was combined with the same dose of Telmisartan (3mg/kg). In addition, the mass of the fibrotic kidney was lower than the negative control (p less than 0.001). Original Source: Breathtec Biomedical Inc, 2019. Found on website: Released to ICIS 14 Feb 2019[This article was prepared by Chemical Business NewsBase (CBNB), a third party premium option available through ICIS news. For any queries about the content please contact: John Godfrey,, +44 (0) 1223 463167] SHARE THIS STORY

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Breathtec Biomedical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Breathtec Biomedical is included in 5 Expert Collections, including Medical Devices.


Medical Devices

7,870 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Infectious Disease

2,225 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.


Health Monitoring & Diagnostics

2,391 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,750 items

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.